Dynavax Technologies Revenue

Dynavax Technologies had revenue of $94.88M in the quarter ending September 30, 2025, with 17.67% growth. This brings the company's revenue in the last twelve months to $330.51M, up 26.73% year-over-year. In the year 2024, Dynavax Technologies had annual revenue of $277.25M with 19.36% growth.

Revenue (ttm)

$330.51M

Revenue Growth

+26.73%

P/S Ratio

5.74

Revenue / Employee

$816,084

Employees

405

Market Cap

1.76B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	277.25M	44.96M	19.36%
Dec 31, 2023	232.28M	-490.40M	-67.86%
Dec 31, 2022	722.68M	283.24M	64.45%
Dec 31, 2021	439.44M	399.19M	991.75%
Dec 31, 2020	40.25M	5.03M	14.29%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

DVAX News

24 days ago - Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 - PRNewsWire
2 months ago - Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying - Investopedia
2 months ago - This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. - Barrons
2 months ago - Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37% - Invezz
2 months ago - Sanofi to acquire US biotech Dynavax for $2.2 billion - Reuters
2 months ago - Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal - WSJ
2 months ago - Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline - PRNewsWire
2 months ago - Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline - GlobeNewsWire

More News